WO1999063928A2 - Pharmaceutical product for hemophilia and asthmatic bronchitis treatment - Google Patents

Pharmaceutical product for hemophilia and asthmatic bronchitis treatment Download PDF

Info

Publication number
WO1999063928A2
WO1999063928A2 PCT/BR1999/000042 BR9900042W WO9963928A2 WO 1999063928 A2 WO1999063928 A2 WO 1999063928A2 BR 9900042 W BR9900042 W BR 9900042W WO 9963928 A2 WO9963928 A2 WO 9963928A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical product
molecular chain
hemophilia
glucosamine
asthmatic bronchitis
Prior art date
Application number
PCT/BR1999/000042
Other languages
French (fr)
Other versions
WO1999063928A3 (en
Inventor
Akira Yoshitome
Eiji Sato
Naul Ozi
Original Assignee
Akira Yoshitome
Eiji Sato
Naul Ozi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akira Yoshitome, Eiji Sato, Naul Ozi filed Critical Akira Yoshitome
Priority to AU45943/99A priority Critical patent/AU4594399A/en
Publication of WO1999063928A2 publication Critical patent/WO1999063928A2/en
Publication of WO1999063928A3 publication Critical patent/WO1999063928A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment, with effective and longstanding use, similar state-of-the-art products being unknown.
  • the main objective of the present invention is to supply a pharmaceutical product for hemophilia and asthmatic bronchitis treatment that seeks to live up the suffering of the people who have these problems.
  • the pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers.
  • the pharmaceutical product of the present invention is a natural polymer composed by a molecular chain comprising of 5 to 850 monomers, being said polymer classified according to the set below, with its related acting ratios.
  • - ⁇ -l,4-poly-N-acetyl-D-glucosamine with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 5% to 40%;
  • the ratio of both chain monomers will yield the pharmaceutical product of the present invention.
  • the pharmaceutical product of the present invention is useful in the treatment and the relief of internal and external bleeding of hemophilic people, and normalizes the breathing of people who suffer from asthmatic bronchitis, acting as an active ingredient for inhibiting its symptoms and effects.
  • the pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is natural biologic product, in powder form, that it should be ingested orally, in the tablet form, encapsulated or mixed in the feeding. Besides its therapeutic effects, said product may be further taken as a nutritional supplement, thus allowing its customer, to improve the efficacy of some organs or glands, regardless of any disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment comprising a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers, being said polymer classified according to the set below, with its related acting ratios: a) β-1,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %; and b) β-1,4-poly-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %.

Description

PHARMACEUTICAL PRODUCT FOR HEMOPHILIA AND ASTHMATIC BRONCHITIS TREATMENT
The present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment, with effective and longstanding use, similar state-of-the-art products being unknown.
The researches currently developed to heal or to reduce the asthmatic bronchitis and hemophilia effects have been, in some manner, ineffective or palliative. The main objective of the present invention is to supply a pharmaceutical product for hemophilia and asthmatic bronchitis treatment that seeks to live up the suffering of the people who have these problems.
The pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers.
Preferably, the pharmaceutical product of the present invention is a natural polymer composed by a molecular chain comprising of 5 to 850 monomers, being said polymer classified according to the set below, with its related acting ratios. - β-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 5% to 40%; and
- β-l,4-poly-D-glucosamine, with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 60% to 95%.
The ratio of both chain monomers will yield the pharmaceutical product of the present invention.
The pharmaceutical product of the present invention- is useful in the treatment and the relief of internal and external bleeding of hemophilic people, and normalizes the breathing of people who suffer from asthmatic bronchitis, acting as an active ingredient for inhibiting its symptoms and effects.
The pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is natural biologic product, in powder form, that it should be ingested orally, in the tablet form, encapsulated or mixed in the feeding. Besides its therapeutic effects, said product may be further taken as a nutritional supplement, thus allowing its customer, to improve the efficacy of some organs or glands, regardless of any disease.

Claims

CLAIM
1. Pharmaceutical product for hemophilia and asthmatic bronchitis treatment, comprising a natural polymer of β-l,4-poly-N-acetyl- D-glucosamine and β-l,4-ρoly-D-glucosamine.
2. Pharmaceutical product as in claim 1 wherein the ratio of ╬▓-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain, is in the range 0% to 100%.
3. Pharmaceutical product as in claim 2 wherein the ratio of ╬▓-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain, is in the range 5% to 40%.
4. Pharmaceutical product as in claim 1 wherein the ratio of ╬▓-l,4-poly-N-glucosamine, with a fractionated molecular chain, is in the range 0% to 100%.
5. Pharmaceutical product as in claim 4 wherein the ratio of ╬▓-l,4-poly-N-glucosamine, with a fractionated molecular chain, is in the range 60% to 95%.
6. Pharmaceutical product as in claim 1 wherein said polymer is composed by a molecular chain of 1 to 5000 monomers.
7. Pharmaceutical product as in claim 6 wherein said polymer is composed by a molecular chain of 5 to 850 monomers.
PCT/BR1999/000042 1998-06-09 1999-06-09 Pharmaceutical product for hemophilia and asthmatic bronchitis treatment WO1999063928A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45943/99A AU4594399A (en) 1998-06-09 1999-06-09 Pharmaceutical product for hemophilia and asthmatic bronchitis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI9806540-8 1998-06-09
BR9806540-8A BR9806540C1 (en) 1998-06-09 1998-06-09 Pharmaceutical product for the treatment of hemophilia and asthmatic bronchitis

Publications (2)

Publication Number Publication Date
WO1999063928A2 true WO1999063928A2 (en) 1999-12-16
WO1999063928A3 WO1999063928A3 (en) 2000-02-03

Family

ID=4071490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR1999/000042 WO1999063928A2 (en) 1998-06-09 1999-06-09 Pharmaceutical product for hemophilia and asthmatic bronchitis treatment

Country Status (3)

Country Link
AU (1) AU4594399A (en)
BR (1) BR9806540C1 (en)
WO (1) WO1999063928A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation
WO1996041818A1 (en) * 1995-06-09 1996-12-27 Drohan William N Chitin hydrogels, methods of their production and use
WO1998004133A1 (en) * 1996-07-29 1998-02-05 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation
WO1996041818A1 (en) * 1995-06-09 1996-12-27 Drohan William N Chitin hydrogels, methods of their production and use
WO1998004133A1 (en) * 1996-07-29 1998-02-05 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin

Also Published As

Publication number Publication date
BR9806540A (en) 2001-03-06
WO1999063928A3 (en) 2000-02-03
BR9806540C1 (en) 2001-05-08
AU4594399A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
CA2240161A1 (en) Antifungal compositions with improved bioavailability
BG104680A (en) Celecoxib compositions
WO2003013428A3 (en) Nutritional supplements and methods of using same
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
US20020164317A1 (en) Cancer immune composition for prevention and treatment of individuals
AU4879596A (en) Amino acid compositions and use thereof in clinical nutrition
EP0149872A2 (en) Cosmetic composition containing glycoproteins for the skin care
EP1393734A4 (en) Drugs for intestinal diseases
JO3001B1 (en) Dietarysupplement for use in treating and/or inhibiting digestive tract ulcers
CA1273874A (en) Appetite moderating and anti-gastritis composition
WO1996022305A3 (en) Modified peptides
JPWO2006038690A1 (en) Functional food and drink
WO1999063928A2 (en) Pharmaceutical product for hemophilia and asthmatic bronchitis treatment
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
HUP0203379A2 (en) Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
PL1768682T3 (en) Product of vegetal origin comprising proanthocyanidines and its preparation process
WO2004030684A3 (en) Kavalactone product
US11896611B1 (en) Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
CN109248255A (en) Propolis drops canker sore is dedicated
US6824798B2 (en) Method of preventing veisalgia
US9226906B2 (en) Method and nutritional supplement for enhancing weight gain of a mammal
US20080145409A1 (en) Composition for the treatment and prevention of peptic ulcer
RU1826910C (en) Biostimulating agent
Suryasree et al. Investigations on the Ulcer protection ability of various extracts of Crossandra benoistii L.
RU2165253C2 (en) Method of treatment of patients with oncological diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA